Hyperion Therapeutics: Zacks Upgrades Hyperion Therapeutics to "Buy" (HPTX)

Hyperion Therapeutics (NASDAQ:HPTX) was upgraded by Zacks from a "hold" rating to a "buy" rating in a report issued on Monday. The firm currently has a $52.00 target price on the stock. Zacks's price objective would suggest a potential upside of 13.07% from the stock's previous close. Zacks' analyst wrote, "Hyperion Therapeutics, Inc. is a [...]This article (Zacks Upgrades Hyperion Therapeutics to "Buy" (HPTX)) was originally developed by and is property of American Banking News.Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.